Norris Perne & French LLP MI lessened its holdings in shares of Catalent Inc (NYSE:CTLT) by 1.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 214,354 shares of the company’s stock after selling 3,491 shares during the period. Norris Perne & French LLP MI owned 0.16% of Catalent worth $8,806,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Zions Bancorporation acquired a new stake in shares of Catalent during the 3rd quarter worth about $100,000. Quantbot Technologies LP raised its position in shares of Catalent by 110.7% during the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after acquiring an additional 1,804 shares in the last quarter. First Bank & Trust raised its position in shares of Catalent by 54.2% during the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after acquiring an additional 1,323 shares in the last quarter. Fortaleza Asset Management Inc. acquired a new stake in shares of Catalent during the 3rd quarter worth about $164,000. Finally, Advisor Group Inc. raised its position in shares of Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after acquiring an additional 65 shares in the last quarter. 98.88% of the stock is currently owned by institutional investors and hedge funds.
In other Catalent news, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Uwe Roehrhoff bought 7,500 shares of the stock in a transaction on Tuesday, November 21st. The stock was bought at an average price of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. Company insiders own 1.70% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. First Analysis initiated coverage on Catalent in a research report on Friday, January 5th. They set an “equal weight” rating on the stock. Royal Bank of Canada initiated coverage on Catalent in a research report on Wednesday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, BidaskClub lowered Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Catalent currently has an average rating of “Buy” and an average target price of $44.44.
Catalent Inc (NYSE:CTLT) traded up $0.76 on Tuesday, reaching $43.70. The company’s stock had a trading volume of 600,800 shares, compared to its average volume of 649,579. The firm has a market capitalization of $5,950.00, a price-to-earnings ratio of 50.81, a price-to-earnings-growth ratio of 2.73 and a beta of 1.41. Catalent Inc has a 52 week low of $25.89 and a 52 week high of $43.71. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same quarter in the previous year, the company posted $0.16 earnings per share. The firm’s revenue was up 23.0% compared to the same quarter last year. sell-side analysts predict that Catalent Inc will post 1.47 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Catalent Inc (CTLT) Shares Sold by Norris Perne & French LLP MI” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/23/catalent-inc-ctlt-shares-sold-by-norris-perne-french-llp-mi.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.